LONDON, ON, and BOSTON, MA--(Marketwired - August 23, 2016) - Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company") a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced the official opening of its U.S. headquarters in Boston, Massachusetts. The new office space is located at 127 Main Street, in close proximity to the plethora of life science companies and teaching hospitals in the area.

"I am thrilled to be heading up our Boston office and spearheading several key functions out of this site, including public and investor relations, corporate and business development and clinical operations," said Alison Silva, President. "The Boston area is the leading biotechnology and life sciences hub in the world and offers innovative biotech companies such as COTI access to world-class talent, investors, and collaboration partners."

The opening of the Boston location affirms the Company's commitment to improving its visibility and profile in the U.S. market. COTI transitioned into a clinical-stage organization earlier this year, highlighted by the ongoing Phase 1 clinical study targeting gynecological cancers at two preeminent U.S. cancer institutions. The Company has now reached an important inflection point that requires better access to the large U.S. life science markets and investment community.

"Gaining a foothold in the U.S. has been a strategic objective of ours and part of my vision for the Company," said Wayne Danter, Chief Executive Officer. "Obtaining our listing on the OTCQB back in June of 2014 to enable investments from American investors was the first step to improving our visibility and exposure in the U.S. Since then we have been introduced to, and established relationships with, many industry leaders and life sciences investors. I believe that with the opening of our Boston office we are very well poised to build and expand these relationships as we rapidly advance our clinical programs."

On June 16, 2014, the Company commenced trading in the United States on the OTC Markets OTCQB trading platform for venture companies under the symbol COTQF. The OTCQB platform has enabled U.S.-based investors to obtain information about the Company and invest through a trading platform familiar to them.

About Critical Outcome Technologies Inc.

COTI is a clinical stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer. The Company's lead compound, COTI‐2, has a novel p53‐dependent mechanism of action with selective and potent anti‐cancer activity. COTI‐2 is being initially evaluated for the treatment of gynecologic cancers, which includes ovarian, cervical, and endometrial cancers in a Phase 1 clinical trial at the MD Anderson Cancer Center at the University of Texas and the Lurie Cancer Center at Northwestern University. The Company has secured orphan drug status in the U.S. for COTI‐2 for the treatment of ovarian cancer in patients failing first line therapies and is planning additional studies in other cancer indications such as head and neck, Li‐Fraumeni Syndrome, and acute myelogenous leukemia, based upon more than ten animal xenograft models showing both single and combination agent activity of COTI‐2 with other leading cancer drugs. Preclinical data provides evidence to suggest a potentially dramatic change in the treatment of cancers with mutations of the p53 gene.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.